Background: Alzheimer's disease (AD) dementia progresses from preclinical brain changes, through mild cognitive impairment (MCI), to AD with dementia. Early diagnosis and confirmation of underlying AD pathology is crucial; however, there is still much to learn about patients' diagnostic journey. We aimed to describe the diagnostic journey and barriers to diagnosis for patients with MCI or dementia due to AD in Canada.

Method: Data were collected from the Adelphi Real World AD Disease Specific Programme (DSP)™, a cross-sectional survey of general practitioners (GPs) and specialists in Canada, from March to October 2023. GP surveys covered patient management and referral patterns. Specialists completed a survey capturing attitudes towards diagnosis, advanced testing, and future treatment landscape. Physicians saw ≥5 (GPs) or ≥10 (specialists) patients per week with MCI or dementia/AD. Analyses are descriptive.

Result: The survey was completed by 20 GPs and 30 specialists (19 neurologists, 6 psychiatrists, and 5 geriatricians). GPs reported patient difficulty remembering people's names (65%) was the patient complaint that most often prompted further testing (Table 1). Other important patient complaints were problems concentrating on everyday tasks (45%) and worry about forgetting things, such as appointments so they have to rely on notes and calendars (45%). GPs reported referring an average of 25±22% of patients with MCI to a specialist after seeing them an average of 3.9±1.3 times. On average, 49±28% of patients with MCI or dementia/AD managed by GPs were not referred to a specialist. Specialists reported the top three barriers to early identification of patients with MCI and patients with mild dementia due to AD were delay due to lack of awareness of the condition (67% and 53%), lack of understanding what constitutes "normal" ageing (63% and 40%), and slow referral (37% and 40%) (Figure 1).

Conclusion: Many patients with MCI or dementia/AD in Canada are not referred by GPs, especially in early-stage AD. Referrals from GPs were also often delayed, with specialists citing delay due to lack of patient awareness of MCI as the main barrier to early diagnosis. Improving awareness of early AD symptoms and AD pathology, and accelerating access to specialists, are warranted.

Download full-text PDF

Source
http://dx.doi.org/10.1002/alz.095446DOI Listing

Publication Analysis

Top Keywords

patients mci
20
mci dementia/ad
12
mci
8
mci dementia
8
early diagnosis
8
diagnostic journey
8
gps
8
gps specialists
8
gps reported
8
delay lack
8

Similar Publications

Introduction: Driving safety may be compromised in people with dementia or mild cognitive impairment (MCI). Occupational therapists assess and screen for driving safety in older people with cognitive impairment. However, little is known about their perspectives relating to these assessments.

View Article and Find Full Text PDF

Mild behavioral impairment in idiopathic REM sleep behavior disorder and Lewy body disease continuum.

J Neural Transm (Vienna)

January 2025

Department of Neurology, Seoul Metropolitan Government-Seoul National University Boramae Medical Center, Seoul National University of College of Medicine, Seoul, Republic of Korea.

To investigate the clinical impact of mild behavioral impairment (MBI) in a predefined cohort with Lewy body disease (LBD) continuum. Eighty-four patients in the LBD continuum participated in this study, including 35 patients with video-polysomnography-confirmed idiopathic REM sleep behavior disorder (iRBD) and 49 clinically established LBD. Evaluations included the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS), neuropsychological tests, and MBI Checklist (MBI-C).

View Article and Find Full Text PDF

Biomarkers.

Alzheimers Dement

December 2024

Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea, Republic of (South).

Background: Normative percentile (NP) quantifies brain atrophy by comparing regional brain volumes of a subject against age and sex-matched cognitively normal populations. Accurate intracranial volume (ICV) adjustment is vital in NP quantification to minimize the effect of an individual's head size. However, which intracranial volume adjustment method yields reliable normative percentiles remains unclear.

View Article and Find Full Text PDF

Background: Reactive astrogliosis refers to functional and morphological changes in astrocytes that occur with neuronal damage in numerous neurological conditions. PET tracers targeting monoamine oxidase B (MAO-B) are used to visualize reactive astrogliosis in the living brain. [F]SMBT-1, a MAO-B selective PET tracer, was developed by modifying the chemical structure of [F]THK5351.

View Article and Find Full Text PDF

Biomarkers.

Alzheimers Dement

December 2024

Roche Diagnostics International AG, Rotkreuz, Zug, Switzerland.

Background: Use of neuroimaging [e.g. magnetic resonance imaging (MRI), positron emission tomography (PET), or computed tomography (CT) scan], cerebrospinal fluid (CSF), and blood biomarker tests can contribute to a more accurate and earlier diagnosis of Alzheimer's disease (AD).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!